Centre of Research Excellence in Pulmonary Fibrosis

Lung Foundation Australia
Pulmonary Fibrosis Clinical Trials

PACT – Patient
New Clinical Trial and Research

Trial title	A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Trial synopsis	This is a study to evaluate the effectiveness and safety of axatilimab given for 52 weeks to patients with IPF. Patients will randomly (like flipping a coin) receive axatilimab or placebo (containing no medication) infusion (an injection into the vein) every two weeks. The effect of axatilimab on IPF will be measured through pulmonary function tests (PFTs), 6-minute walk tests and by assessing patients' IPF symptoms (including breathing and cough) using standard questionnaires.
Investigational medicinal product	Axatilimab
Disease target	Idiopathic Pulmonary Fibrosis (IPF)
Sponsor	Syndax Pharmaceuticals, Inc.
Duration	Patients will participate in the study for up to 70 weeks, including an 8 week Screening Period, a 52-week Treatment Period, and a 10-week Follow-up Period that includes a Follow-up telephone call 28 days post final dose and an ADA blood test Follow-up Visit 12 weeks post final dose.
Trial Status	Not yet recruiting
Lead site(s) in Australia	Lung Research Queensland
Lead site(s) in New Zealand	
Additional sites	
Contact	pactcoordinator@cre-pf.org.au